• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Oxidative Medicine and Cellular Longevity >Vasorelaxant Effect of a New Hydrogen Sulfide-Nitric Oxide Conjugated Donor in Isolated Rat Aortic Rings through cGMP Pathway
【2h】

Vasorelaxant Effect of a New Hydrogen Sulfide-Nitric Oxide Conjugated Donor in Isolated Rat Aortic Rings through cGMP Pathway

机译：新型硫化氢一氧化氮共轭供体在离体大鼠主动脉环中通过cGMP途径的血管舒张作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Endothelium-dependent vasorelaxant injury leads to a lot of cardiovascular diseases. Both hydrogen sulfide (H2S) and nitric oxide (NO) are gasotransmitters, which play a critical role in regulating vascular tone. However, the interaction between H2S and NO in vasorelaxation is still unclear. ZYZ-803 was a novel H2S and NO conjugated donor developed by H2S-releasing moiety (S-propyl-L-cysteine (SPRC)) and NO-releasing moiety (furoxan). ZYZ-803 could time- and dose-dependently relax the sustained contraction induced by PE in rat aortic rings, with potencies of 1.5- to 100-fold greater than that of furoxan and SPRC. Inhibition of the generations of H2S and NO with respective inhibitors abolished the vasorelaxant effect of ZYZ-803. ZYZ-803 increased cGMP level and the activity of vasodilator stimulated phosphoprotein (VASP) in aortic rings, and those effects could be suppressed by the inhibitory generation of H2S and NO. Both the inhibitor of protein kinase G (KT5823) and the inhibitor of KATP channel (glibenclamide) suppressed the vasorelaxant effect of ZYZ-803. Our results demonstrated that H2S and NO generation from ZYZ-803 cooperatively regulated vascular tone through cGMP pathway, which indicated that ZYZ-803 had therapeutic potential in cardiovascular diseases.
机译：内皮依赖性血管舒张损伤导致许多心血管疾病。硫化氢（H2S）和一氧化氮（NO）都是气体传输剂，它们在调节血管张力方面起着关键作用。但是，尚不清楚H2S和NO在血管舒张中的相互作用。 ZYZ-803是由H2S释放部分（S-丙基-L-半胱氨酸（SPRC））和NO释放部分（呋喃喃）开发的新型H2S和NO共轭供体。 ZYZ-803可以在时间和剂量上放松PE诱导的大鼠主动脉环的持续收缩，其效力是呋喃山和SPRC的1.5至100倍。用相应的抑制剂抑制H2S和NO的产生消除了ZYZ-803的血管舒张作用。 ZYZ-803增加了cGMP水平和主动脉环中血管舒张剂刺激的磷蛋白（VASP）的活性，并且可以通过抑制H2S和NO的产生来抑制这些作用。蛋白激酶G的抑制剂（KT5823）和KATP通道的抑制剂（格列本脲）均抑制ZYZ-803的血管舒张作用。我们的结果表明ZYZ-803产生的H2S和NO通过cGMP途径协同调节血管紧张度，这表明ZYZ-803在心血管疾病中具有治疗潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号